<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Byrne, Christopher</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">NAFLD: CV Risk Regardless of Hyperglycemia or Obesity</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-13</style></pages><abstract><style  face="normal" font="default" size="100%">The prevalence of nonalcoholic fatty liver disease (NAFLD) has been estimated to be between 20% and 30% in the general population, but this value is much higher (approximately 70% to 80%) in individuals with type 2 diabetes. Increasing recognition of NAFLD and its strong relationship with metabolic syndrome has stimulated an interest in its possible role in the development of cardiovascular disease [Targher G et al. Diabetologia 2008].</style></abstract><number><style face="normal" font="default" size="100%">11</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>